ATH While Everything Else Wobbles: Pharma Is The New Safe Haven
Pharma’s quiet reawakening
While the broader market trades lower, U.S. pharmaceutical equities are breaking to fresh all-time highs. After years of underperformance, large-cap biopharma is benefiting from steady earnings, improving sales revisions and valuations that remain near rock-bottom relative to the S&P 500.